NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and provided more evidence on its effectiveness.
Nab-paclitaxel, also known as Abraxane, made by Celgene will be routinely available as an option for patients with pancreatic cancer that has progressed.
When Abraxane is added to a standard chemotherapy, called gemcibatine the evidence has found it extends life by an average of 2.4 months.
If other combination chemotherapy treatments are unsuitable for a patient, NICE recommends offering Abraxane instead of this standard chemotherapy on its own.
It works by blocking the action of the proteins within cancer cells that cause them to grow and divide.
NICE has reviewed its guidance from 2015 which did not recommend Abraxane for routine NHS use for not being cost-effective.
Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: “The life expectancy of pancreatic cancer is poor, with patients usually living for only up to 6 months. It’s incredibly important that patients and families affected by this disease are able to have routine access to this life extending treatment.”
There are almost 10,000 new cases of pancreatic cancer each year in the UK, and less than 1% survive for 10 or more years.
This is a final appraisal determination for Abraxane. The company, healthcare professionals and patient/carer organisations now have until Friday 1 September to appeal the decision.
To read more Press Release articles, click here.